| n |
234 |
133 |
101 |
|
| Age (years) |
71 ± 9.2 |
71 ± 8.9 |
70 ± 9.5 |
0.223 |
| Gender (Male), n= |
155 (66%) |
85 (64%) |
70 (69%) |
0.387 |
| ECOG-PS > 1, n = |
5 (2.1%) |
4 (3.0%) |
1 (1.0%) |
0.393 |
| Hypertension, n = |
106 (44%) |
65 (49%) |
41 (41%) |
0.234 |
| Diabetes mellitus, n = |
39 (17%) |
19 (14%) |
20 (20%) |
0.291 |
| Cardiovascular disease, n = |
39 (17%) |
23 (17%) |
16 (16%) |
0.768 |
| Smoking, n = |
102 (44%) |
52 (39%) |
50 (50%) |
0.112 |
| eGFR before surgery (mL/min/1.73m2) |
56 ± 18 |
56 ± 19 |
57 ± 15 |
0.414 |
| Hydronephrosis, n= |
164 (70%) |
96 (72%) |
68 (67%) |
0.422 |
| NAC regimen: GCis / GCarbo / others, n = |
|
|
21 /76 /4 |
|
| cT 2/3/4, n = |
5 / 217 / 12 |
4 / 123 / 6 |
1 / 94 / 6 |
0.566 |
| cN+, n = |
34 (15%) |
15 (11%) |
19 (19%) |
0.105 |
| Original tumor sites, n = |
|
|
|
|
| Renal pelvis / Ureter / Multiple |
92 / 125 / 17 |
61 / 61 / 11 |
31 / 64 / 6 |
0.009 |
| Laparoscopic surgery, n = |
48 (21%) |
17 (13%) |
31 (31%) |
0.001 |
| Postoperative complications, n = |
|
|
|
|
| All |
33 (14%) |
16 (12%) |
17 (17%) |
0.296 |
| G3 |
8 (3.4%) |
6 (4.5%) |
2 (2.0%) |
|
| Pathological outcomes, n = |
|
|
|
|
| pT3 or 4 |
141 (60%) |
105 (79%) |
36 (36%) |
< 0.001 |
| Downstaging |
58 (25%) |
19 (14%) |
39 (39%) |
< 0.001 |
| Downstaging (cT - pT) |
0.6 ± 1.0 |
0.3 ± 0.8 |
1.1 ± 1.0 |
< 0.001 |
| pN+ |
27 (12%) |
16 (12%) |
11 (11%) |
0.787 |
| High grade |
222 (95%) |
127 (96%) |
95 (94%) |
0.623 |
| Concomitant CIS |
22 (9.4%) |
10 (7.5%) |
12 (12%) |
0.257 |
| Surgical margin positive |
14 (6.0%) |
9 (6.8%) |
5 (5.0%) |
0.562 |
| Lymphovascular invasion |
87 (37%) |
61 (46%) |
26 (26%) |
0.004 |
| Median follow-up (Months) |
27 |
30 |
26 |
|
